McKinsey Issues a Rare Apology for Its Role in OxyContin Sales

The firm faced criticism after a report revealed that consultants had discussed destroying documents related to the opioid business and proposed that a drugmaker pay its distributors rebates for overdoses.

View original article
Contributor: Walt Bogdanich and Michael Forsythe